NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while falling tech stocks pressured the S&P 500 and Nasdaq lower. The Dow Jones Industrial Average gained 0.24 percent to close at a record 24,290.05. The S&P 500 Index declined 0.11 percent to close at 2,639.44 and the Nasdaq Composite Index dropped 1.05 percent to close at 6,775.37. Financial stocks appear to be the early benefactors from a potential tax overhaul as the Financial Select Sector SPDR Fund ETF spiked 1.52 percent on Monday and is up 6.8 percent in the past week.

"Investors this week will look to see progress between the House and Senate's joint bill," said Nicholas Colas, co-founder of DataTrek Research. "Both chambers still have to reconcile differences between their bills, such as implementing corporate tax cuts immediately or in 2019."

RDI Initiates Coverage on:

Achillion Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ACHN

Zynerba Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ZYNE

Achillion Pharmaceuticals, Inc.'s stock edged 0.99% lower Monday, to close the day at $2.99. The stock recorded a trading volume of 5,466,168 shares, which was above its three months average volume of 1,910,344 shares. In the last year, Achillion Pharmaceuticals, Inc.'s shares have traded in a range of 2.92 - 5.66. The stock is currently trading 47.17% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.74 is below its 200-day moving average of $4.27. Shares of Achillion Pharmaceuticals have fallen roughly 26.17 percent in the past month and are down 27.6 percent year-to-date.

Access RDI's Achillion Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ACHN

On Monday, shares in Zynerba Pharmaceuticals, Inc. recorded a trading volume of 1,219,493 shares, which was above the three months average volume of 752,053 shares. The stock ended the day 8.30% lower at 13.37. The share price has gained 146.68% from its 52-week low with a 52-week trading range of 5.42 - 25.95.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $11.62 is below its 200-day moving average of $12.50. Shares of Zynerba Pharmaceuticals have gained roughly 29.43 percent in the past month and are down 14.24 percent year-to-date.

Access RDI's Zynerba Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ZYNE

Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com